5 September 2024

Liège-Herstal, Belgium

KiOmed Pharma announces that its partner Hansoh Pharma has successfully initiated the clinical trial for its product KioMedine^vsone.

“We are excited to achieve this key milestone in collaboration with our partner Hansoh Pharma as it paves the way for our product approval in China, where more than 100 million patients are suffering from Osteoarthritis,” stated François Blondel, Executive Chairman and founder. “We are proud to see this milestone achieved in 2024 as we will soon be celebrating KiOmed’s 10th anniversary,” he added.

This strategic milestone is achieved in the framework of the license agreement for the development and commercialization of KioMedine^vsone, a carboxymethyl chitosan injection, in China signed with Hansoh Pharma in September 2022.

According to a recent epidemiology report, the prevalence of knee osteoarthritis in China is 8.1%. As the population in China is aging rapidly, the disease burden caused by knee osteoarthritis continues to rise while safe and effective treatment options are still lacking.

“We wish to congratulate both teams for achieving this key step forward in the development of KioMedine^vsone in China. This result is a world-first as KioMedine^vsone will be the first non-animal chitosan capable of relieving OA pain for more than 6 months after only one injection,” stated Dr. Houtaï Choumane, CEO.

About KiOmed Pharma

KiOmed Pharma is a commercial-stage specialty pharma with KiOmedine® a unique worldwide patented and commercially approved technology addressing a $+20 Bn market in Osteoarthritis (OA), Aesthetic medicine and Eye care (ophthalmology). KiOmed Pharma is the only company worldwide producing exclusive and highly purified non-animal CM-chitosan (KiOmedine®), a disruptive polysaccharide technology improving quality of life for millions. The company has launched KioMedine^vsone product, its first market entry in OA, which is gaining strong market traction and represents a game-changer for the quality of life of millions of patients suffering from refractory osteoarthritis. The company has secured 2 major partnerships with blue chip companies active in OA (Hansoh Pharma-China) and Aesthetic (Sinclair Pharma-UK) markets.